A Phase 3, Randomized, Double-Blind, Vehicle-Controlled Efficacy and Safety Study of Glycopyrronium in Subjects With Axillary Hyperhydrosis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 26 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Mar 2019 According to a Dermira media release, results of post hoc analysis from ATMOS-1 and ATMOS-2 studies were presented at the Annual Meeting of the American Academy of Dermatology (AAD) 2019.
01 Mar 2019 Results of post hoc analysis from ATMOS-1 and ATMOS-2 studies presented in a Dermira media release.
26 Feb 2019 According to a Dermira media release, data from post hoc analyses of the ATMOS-1 and ATMOS-2 will be presented at the 77th Annual Meeting of the American Academy of Dermatology (AAD).

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com